A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
- Conditions
- Solid Tumor
- Interventions
- Drug: 68Ga-FAP-2286Drug: 177Lu-FAP-2286
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 222
- Registration Number
- NCT04939610
- Locations
- πΊπΈ
UCSF Medical Center, San Francisco, California, United States
πΊπΈMayo Clinic, Rochester, Minnesota, United States
πΊπΈColumbia University Medical Center, New York, New York, United States
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
- Conditions
- Active Secondary Progressive Multiple SclerosisRelapsing-remitting Multiple Sclerosis
- Interventions
- Other: Kesimpta
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 367
- Registration Number
- NCT04940065
- Locations
- π―π΅
Novartis Investigative Site, Wakayama, Japan
Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 153
- Registration Number
- NCT04940052
- Locations
- πΊπΈ
Northwestern University Med School, Chicago, Illinois, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
π»π³Novartis Investigative Site, Hanoi, Vietnam
Russian Registry of Patients With nAMD
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Other: nAMD
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2665
- Registration Number
- NCT04935411
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 511
- Registration Number
- NCT04935359
- Locations
- πΊπΈ
Highlands Oncology Group, Fayetteville, Arkansas, United States
πΊπΈUniversity of California LA, Los Angeles, California, United States
πΊπΈAdvent Health Cancer Institute, Orlando, Florida, United States
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
- Conditions
- Multiple Sclerosis
- Interventions
- Other: Siponimod
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 867
- Registration Number
- NCT04933552
- Locations
- πΊπΈ
Novartis Investigative Site, La Jolla, California, United States
A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 450
- Registration Number
- NCT04929249
- Locations
- πΊπΈ
ARcare Center for Clinical Research ., Little Rock, Arkansas, United States
πΊπΈARcare Center for Clinical Research, Little Rock, Arkansas, United States
πΊπΈKeck Medical Center USC ., Los Angeles, California, United States
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
- Conditions
- Giant Cell Arteritis (GCA)
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 354
- Registration Number
- NCT04930094
- Locations
- πΊπΈ
Sarasota Arthritis Research Center, Sarasota, Florida, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈCedars Sinai Medical Center ., Los Angeles, California, United States
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT04926831
- Locations
- πΊπΈ
UCLA Oncology Hematology, La Jolla, California, United States
πΊπΈUniversity of California Davis Cancer Center, Sacramento, California, United States
πΊπΈFairfax Northern Virginia Hem Onc, Fairfax, Virginia, United States
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Drug: OfatumumabDrug: SiponimodDrug: FingolimodOther: Ofatumumab placeboOther: Siponimod placeboOther: Fingolimod placebo
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT04926818
- Locations
- πΊπΈ
Arkansas Childrens Hosp Rsch Inst, Little Rock, Arkansas, United States
πΊπΈChildrens Hospital Los Angeles, Los Angeles, California, United States
πΊπΈUniversity of California San Diego, San Diego, California, United States